Investigation of plasma metabolomics and neurotransmitter dysfunction in the process of Alzheimer's disease rat induced by amyloid beta 25-35

被引:5
|
作者
Wei, Mengying [1 ,2 ]
Liu, Yuanyuan [1 ]
Pi, Zifeng [2 ]
Yue, Kexin [1 ]
Li, Shizhe [3 ]
Hu, Mingxin [1 ]
Liu, Zhiqiang [2 ]
Song, Fengrui [2 ]
Liu, Zhongying [1 ]
机构
[1] Jilin Univ, Sch Pharmaceut Sci, 1266 Fujin Rd, Changchun 130021, Jilin, Peoples R China
[2] Chinese Acad Sci, Changchun Inst Appl Chem, Natl Ctr Mass Spectrometry Changchun, Jilin Prov Key Lab Chinese Med Chem & Mass Spectr, Changchun 130022, Jilin, Peoples R China
[3] Guangdong Univ Technol, Inst Biomed & Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
ARACHIDONIC-ACID; NITRIC-OXIDE; FATTY-ACIDS; DEMENTIA; SYSTEMS; CHOLESTEROL; NEUROINFLAMMATION; HOMOCYSTEINE; INFLAMMATION; HIPPOCAMPUS;
D O I
10.1039/c9ra00302a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Alzheimer's disease (AD) has become one of the major diseases endangering the health of the elderly. Clarifying the features of each AD animal model is valuable for understanding the onset and progression of diseases and developing potential treatments in the pharmaceutical industry. In this study, we aimed to clarify plasma metabolomics and neurotransmitter dysfunction in the process of AD model rat induced by amyloid beta 25-35 (A beta 25-35). Firstly, Morris Water Maze (MWM) test was used to investigate cognitive impairment in AD rat after 2, 4 and 8 weeks of modelling. Based on this, the effects on levels of AD-related enzymes and eight neurotransmitters were analyzed. And plasma metabolomics analysis based on ultra high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS) was used to research the metabolic disturbances in the process of AD rat. The results shown the injury on the spatial learning ability of AD rats was gradually aggravated within 4 weeks, reached the maximum at 4 weeks and then was stable until 8 weeks. During 8 weeks of modeling, the levels of enzymes including beta-secretase, gamma-secretase, glycogen synthase kinase-3 beta (GSK-3 beta), acetyl cholinesterase (AchE) and nitric oxide synthase (NOS) were significant increased in the plasma of AD rats. The neurotransmitter dysfunction was mainly involved in gamma-aminobutyric acid (GABA), acetyl choline (Ach), glutamic acid (Glu), 5-hydroxytryptamine (5-HT), dopamine (DA) and norepinephrine (NE). 17 endogenous metabolites correlated with AD were successfully detected in the metabolomics analysis. These metabolites were mainly involved in fatty acids, sphingolipids, and sterols metabolisms, vitamin metabolism, and amino acid metabolism. These metabolites might be the potential biomarkers that correctly mark different stages of AD. The study on peripheral plasma indices reflecting the process of AD laid the foundation for understand the pathophysiology of AD and find an effective and radical cure. And the rules of endogenous metabolic disorder in AD rats also have a certain guiding significance for the future study of food-drug interactions at different stages of AD.
引用
收藏
页码:18308 / 18319
页数:12
相关论文
共 50 条
  • [31] beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide
    Bitting, L
    Naidu, A
    Cordell, B
    Murphy, GM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (27) : 16084 - 16089
  • [32] Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35)
    Tsunekawa, Hiroko
    Noda, Yukihiro
    Mouri, Akihiro
    Yoneda, Fumio
    Nabeshima, Toshitaka
    BEHAVIOURAL BRAIN RESEARCH, 2008, 190 (02) : 224 - 232
  • [33] Pelargonidin improves memory deficit in amyloid β25-35 rat model of Alzheimer's disease by inhibition of glial activation, cholinesterase, and oxidative stress
    Sohanaki, Hamid
    Baluchnejadmojarad, Tourandokht
    Nikbakht, Farnaz
    Roghani, Mehrdad
    BIOMEDICINE & PHARMACOTHERAPY, 2016, 83 : 85 - 91
  • [34] GSK-3β as a target for apigenin-induced neuroprotection against Aβ 25-35 in a rat model of Alzheimer's disease
    Alsadat, Alireza Moein
    Nikbakht, Farnaz
    Nia, Hadiseh Hossein
    Golab, Fereshteh
    Khadem, Yasaman
    Barati, Mahmoud
    Vazifekhah, Somayeh
    NEUROPEPTIDES, 2021, 90
  • [35] Subcellular and metabolic examination of amyloid-β peptides in Alzheimer disease pathogenesis: Evidence for Aβ25-35
    Kaminsky, Yury G.
    Marlatt, Michael W.
    Smith, Mark A.
    Kosenko, Elena A.
    EXPERIMENTAL NEUROLOGY, 2010, 221 (01) : 26 - 37
  • [36] The Protective Effects of Jatrorrhizine on β-Amyloid (25-35)-Induced Neurotoxicity in Rat Cortical Neurons
    Luo, Tao
    Jiang, Wei
    Kong, Yan
    Li, Sheng
    He, Feng
    Xu, Jie
    Wang, Hua-Qiao
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2012, 11 (08) : 1030 - 1037
  • [37] Induced β-Barrel Formation of the Alzheimer's Aβ25-35 Oligomers on Carbon Nanotube Surfaces: Implication for Amyloid Fibril Inhibition
    Fu, Zhaoming
    Luo, Yin
    Derreumaux, Philippe
    Wei, Guanghong
    BIOPHYSICAL JOURNAL, 2009, 97 (06) : 1795 - 1803
  • [38] Autoimmune responses to amyloid structures of Aβ(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease
    Grudena, MA
    Davudova, TB
    Malisauskas, M
    Zamotin, VV
    Sewell, RDE
    Voskresenskaya, NI
    Kostanyan, IA
    Shrestnev, VV
    Morozova-Roche, LA
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 18 (02) : 165 - 171
  • [39] Protective effect of cyclophilin A against Alzheimer's amyloid beta-peptide (25-35)-induced oxidative stress in PC12 cells
    Ge Yu-song
    Teng Wei-yu
    Zhang Chao-dong
    CHINESE MEDICAL JOURNAL, 2009, 122 (06) : 716 - 724
  • [40] Human platelet calcium mobilisation in response to β-amyloid (25-35):: buffer dependency and unchanged response in Alzheimer's disease
    Hedin, HLM
    Eriksson, S
    Fowler, CJ
    NEUROCHEMISTRY INTERNATIONAL, 2001, 38 (02) : 145 - 151